Cirrhosis Complications (SBP, HRS, HE)

USMLE Step 1 trap: Requires culture positivity to diagnose SBP rather than using the PMN threshold. SBP is diagnosed by ascitic fluid PMN count ≥ 250 cells/mm³ regardless of culture result, and empiric antibiotics should be started immediately.

Cirrhosis complications — SBP, hepatorenal syndrome, and hepatic encephalopathy — are among the highest-yield clinical scenarios on USMLE Step 1. These three conditions share a common upstream driver (portal hypertension and systemic inflammation from cirrhosis), but each has distinct diagnostic thresholds, mechanisms, and treatment logic that the exam exploits separately. Expect vignettes where you have to pick the right intervention or interpret lab values correctly, not just name the condition.

The exam tests these at multiple levels. SBP questions often hinge on whether you know the PMN threshold (not culture results) and when to give IV albumin alongside antibiotics. HRS questions push you to understand the pathophysiology — splanchnic vasodilation causing renal hypoperfusion — so you can justify why vasoconstrictors plus albumin work, and why fluids alone don't. HE questions require knowing both the precipitants to identify in a stem and the combination pharmacotherapy for secondary prevention. USMLE Step 1 frequently embeds these in longer passages where a cirrhotic patient decompensates and you have to sequence the workup or management correctly.

What makes this topic tricky is that the wrong answers are all plausible-sounding partial truths. Culture-negative SBP throws students who expect a positive culture before treating. HRS looks like prerenal AKI on the surface, so students reflexively reach for fluids — which is exactly the wrong anchor. And lactulose, while correct for acute HE, is incomplete without rifaximin for recurrence prevention. Each misconception here reflects a real gap that USMLE Step 1 is specifically designed to expose.

From real student decks

54%have cards covering this topic

30%have mature cards

Common misconceptions

Common mistake

Wrong: SBP requires a positive ascitic fluid culture to diagnose.

Right: SBP is diagnosed by ascitic fluid PMN count ≥ 250 cells/mm³ regardless of culture result, and empiric antibiotics should be started immediately.

Culture results in SBP are often negative (up to 60% of cases) because bacterial concentrations in ascitic fluid are low — waiting for a positive culture before treating is dangerous and incorrect. The diagnosis is made clinically and microbiologically by ascitic fluid PMN count ≥ 250 cells/mm³ alone. On the exam, if the stem gives you that PMN count and asks what to do next, start empiric antibiotics immediately regardless of culture status.

Common mistake

Wrong: HRS is treated with aggressive IV fluid resuscitation alone.

Right: HRS is treated with vasoconstrictors (terlipressin or norepinephrine) plus albumin; the only definitive cure is liver transplantation.

HRS looks like prerenal AKI because the kidneys themselves are structurally normal, but the mechanism is functional — splanchnic vasodilation caused by portal hypertension drops effective arterial pressure, triggering maximal renal vasoconstriction. Giving IV fluids alone cannot reverse this vasoconstriction; you need vasoconstrictors (terlipressin or norepinephrine) to counteract splanchnic dilation plus albumin to expand effective circulating volume. The kidneys recover only when the underlying cirrhosis is corrected — which is why liver transplantation is the definitive treatment.

Common mistake

Wrong: Lactulose alone is sufficient long-term therapy for hepatic encephalopathy.

Right: Rifaximin is added to lactulose for secondary prophylaxis of HE to reduce recurrence.

Lactulose works acutely by acidifying the colon and trapping ammonia as ammonium, but it has limited efficacy for preventing HE recurrence when used alone. Rifaximin is a non-absorbed antibiotic that reduces ammonia-producing gut bacteria and significantly decreases recurrence risk — studies show it cuts HE recurrence by about 58% on top of lactulose. For USMLE Step 1 purposes, the combination of lactulose plus rifaximin is the standard second-line or maintenance regimen after a first HE episode.

Common mistake

Gap: Misses the specific criteria distinguishing primary from secondary SBP prophylaxis

Primary SBP prophylaxis with fluoroquinolones is indicated when ascitic fluid protein is < 1.5 g/dL plus renal or hepatic dysfunction; secondary prophylaxis is indicated after any SBP episode.

Primary SBP prophylaxis isn't given to all cirrhotics with ascites — it targets the highest-risk subset: those with ascitic protein < 1.5 g/dL (low opsonization capacity) AND significant renal or hepatic dysfunction. Secondary prophylaxis, on the other hand, is straightforward: any patient who has had one SBP episode goes on indefinite fluoroquinolone prophylaxis because recurrence rates are very high. The exam will give you a clinical scenario and expect you to distinguish between these two indications rather than applying prophylaxis indiscriminately.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Know the SBP diagnostic threshold: ascitic fluid PMN count ≥ 250 cells/mm³ is sufficient to diagnose SBP and start empiric antibiotics (typically cefotaxime), regardless of whether cultures come back positive.
Know when to give IV albumin with SBP treatment: it's indicated when creatinine > 1 mg/dL, BUN > 30 mg/dL, or bilirubin > 4 mg/dL to prevent hepatorenal syndrome from developing.
Distinguish primary from secondary SBP prophylaxis: primary prophylaxis with norfloxacin or ciprofloxacin is indicated when ascitic protein < 1.5 g/dL combined with significant renal or hepatic dysfunction (Child-Pugh ≥ 9 with bilirubin ≥ 3, or creatinine ≥ 1.2, BUN ≥ 25, or sodium ≤ 130); secondary prophylaxis is indicated after any prior SBP episode.
Understand HRS pathophysiology: extreme splanchnic vasodilation → reduced effective arterial volume → renal vasoconstriction → functional renal failure without intrinsic renal disease; treatment is vasoconstrictors (terlipressin or norepinephrine) plus albumin, with liver transplant as the only cure.
Identify common HE precipitants in a vignette: GI bleed, infection, constipation, hypokalemia, sedating medications, and dietary protein excess — and know that treatment includes lactulose plus rifaximin for secondary prevention of recurrence.

Can you avoid these mistakes?

A cirrhotic patient with ascites undergoes paracentesis. The ascitic fluid shows 320 PMN cells/mm³ and the culture is pending. What is the diagnosis, and what should you do right now?

A cirrhotic patient develops oliguria and rising creatinine. Urine sodium is < 10 mEq/L and urinalysis is bland. You give 1.5L of IV saline over 24 hours with no improvement in creatinine. What is the likely diagnosis, what is the mechanism, and what is the correct treatment?

A cirrhotic patient is discharged after recovering from their first episode of hepatic encephalopathy. What medications should they be sent home on to prevent recurrence, and why is monotherapy insufficient?

A cirrhotic patient has ascitic fluid protein of 1.2 g/dL and a serum creatinine of 1.4 mg/dL but has never had SBP. Does this patient qualify for SBP prophylaxis? What drug class is used, and how does this differ from management after a documented SBP episode?

Cirrhosis Complications (SBP, HRS, HE)

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics